Advances in the treatment of metastatic prostate cancer in China

References

1. 1.↵
   2. Bray F,
   3. Laversanne M,
   4. Sung H,
   5. Ferlay J,
   6. Siegel RL,
   7. Soerjomataram I, et al.

   Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229–63.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. He H,
   3. Liang L,
   4. Han D,
   5. Xu F,
   6. Lyu J.

   Different trends in the incidence and mortality rates of prostate cancer between China and the USA: a joinpoint and age-period-cohort analysis. Front Med (Lausanne). 2022; 9: 824464.
3. 3.↵
   American Cancer Society. Survival Rates for Prostate Cancer; 2025. Available from: https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/survival-rates.html.
4. 4.↵
   2. Chen K,
   3. Jiang K,
   4. Tang L,
   5. Chen X,
   6. Hu J,
   7. Sun F.

   Analysis of clinical trials on therapies for prostate cancer in mainland China and globally from 2010 to 2020. Front Oncol. 2021; 11: 647110.
5. 5.↵
   2. Gu W,
   3. Han W,
   4. Luo H,
   5. Zhou F,
   6. He D,
   7. Ma L, et al.

   Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022; 23: 1249–60.

   OpenUrlPubMed
6. 6.↵
   2. Gao X,
   3. Burris HA,
   4. Vuky J,
   5. Dreicer R,
   6. Sartor AO,
   7. Sternberg CN, et al.

   Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022; 40: 17.

   OpenUrlCrossRef
7. 7.
   2. Daniel PP,
   3. McKean M,
   4. Lang JM,
   5. Gao X,
   6. Dreicer R,
   7. Geynisman DM, et al.

   Shore ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1/2 study. J Clin Oncol. 2024; 42: 5011.

   OpenUrl
8. 8.↵
   2. Fizazi K,
   3. Bernard-Tessier A,
   4. Roubaud G,
   5. Utriainen T,
   6. Barthélémy P,
   7. Fléchon A, et al.

   Targeted inhibition of CYP11A1 in castration-resistant prostate cancer. NEJM Evid. 2023; 3: EVIDoa2300171.
9. 9.↵
   2. Hoskin P,
   3. Sartor O,
   4. O’Sullivan JM,
   5. Johannessen DC,
   6. Helle SI,
   7. Logue J, et al.

   Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014; 15: 1397–406.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Zhou T,
    3. Zhou F,
    4. Guo J,
    5. Shi H,
    6. Yao X,
    7. Guo H, et al.

    Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: a single-arm phase 3 study. Asia Pac J Clin Oncol. 2021; 17: 462–70.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Gillessen S,
    3. Choudhury A,
    4. Saad F,
    5. Gallardo E,
    6. Soares A,
    7. Loriot Y, et al.

    LBA1 – A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333/PEACE-3. Ann Oncol. 2024; 35: 1–72.

    OpenUrlCrossRef
12. 12.↵
    2. Chang SS.

    Overview of prostate-specific membrane antigen. Rev Urol. 2004; 6: S13–8.

    OpenUrl
13. 13.↵
    Novartis. Novartis China Haiyan radioligand manufacturing site construction kick-off ceremony; 2024. Available from: https://www.novartis.com.cn/news/nuohuazhongguofangshexingyaopinshengchanxiangmudianjikaijian.
14. 14.↵
    2. Hofman MS,
    3. Lawrentschuk N,
    4. Francis RJ,
    5. Tang C,
    6. Vela I,
    7. Thomas P, et al.

    Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395: 1208–16.

    OpenUrlCrossRefPubMed
15. 15.
    2. Hussain M,
    3. Mateo J,
    4. Fizazi K,
    5. Saad F,
    6. Shore N,
    7. Sandhu S, et al.

    Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020; 383: 2345–57.

    OpenUrlCrossRefPubMed
16. 16.↵
    2. Clarke NW,
    3. Armstrong AJ,
    4. Thiery-Vuillemin A,
    5. Oya M,
    6. Shore ND,
    7. Procopio G, et al.

    Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023; 41: LBA16.
17. 17.↵
    2. Chi KN,
    3. Rathkopf D,
    4. Smith MR,
    5. Efstathiou E,
    6. Attard G,
    7. Olmos D, et al.

    Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023; 41: 3339–51.

    OpenUrlCrossRefPubMed
18. 18.↵
    2. Agarwal N,
    3. Azad A,
    4. Carles J,
    5. Fay AP,
    6. Matsubara N,
    7. Szczylik C, et al.

    Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. J Clin Oncol. 2025; 43: LBA18.
19. 19.↵
    2. Kwan EM,
    3. Wyatt AW,
    4. Chi KN.

    Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation. Front Oncol. 2022; 12: 1054497.
20. 20.↵
    2. Wu J,
    3. Wei Y,
    4. Pan J,
    5. Jin S,
    6. Gu W,
    7. Gan H, et al.

    Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients. Int J Cancer. 2021; 148: 673–81.

    OpenUrlCrossRefPubMed